Introduction

The term locally advanced non-small cell lung cancer (NSCLC) refers to a large and heterogeneous disease, for which the best therapeutic options [induction treatment, surgery and/or definitive chemo-radiotherapy (CT-RT)] are still under investigation. Patients who underwent surgery alone or definitive CT-RT have reduced long-term survival rates that range from 5% to 25% (1-3). Concurrent CT-RT with high dose radiotherapy has been widely adopted as a chance of cure when patients are considered inoperable. Nevertheless, 24% to 35% of these patients do not respond to the treatment or develop local recurrences and surgery should be considered a “salvage therapy” to improve patients’ survival if other medical treatments are not available (4).

Salvage surgery has an established role in many fields of thoracic oncology, particularly for the treatment of metastatic diseases to the lung (5-8). However, the potential benefits of salvage surgery as a therapeutic option for locally advanced NSCLC after definitive CT-RT is still under debate.

To date, only a few studies report the results of surgery after curative intent CT-RT with high-dose (>59 Gy) radiotherapy. In this brief review, we will address this issue and evaluate the prognosis of patients treated with...
salvage surgery after radical treatment (CT-RT) for locally advanced NSCLC.

Methods

Articles were identified by a computer-assisted search of the literature. Search strategy was applied to PubMed from 1998 to 2019. Key words and terms used included “salvage surgery, non small cell lung cancer, locally advanced non small cell lung cancer, definitive chemoradiotherapy.” The search was further refined using the following limitations: “English language” and “human”.

Definition of salvage surgery

Salvage surgery is defined as the surgical resection of recurrent or persistent NSCLC, at least three months after CT-RT with curative intent in patients initially excluded from surgical resection. All clinical cases require discussion at multidisciplinary lung cancer meeting, and surgery could be considered if there are reasonable chances to obtain an R0 resection and there are no other therapeutic options or in the presence of urgent symptoms such as haemoptysis. Selection of patients is the most critical aspects to obtain positive benefits of salvage surgery, and a careful re-staging should be performed before indicating surgery as salvage therapeutic option. Chest computed tomography (CT) scan and fluorodeoxyglucose (FDG)-positron emission tomography (PET) scan are essential for completing the re-staging when relapse or recurrent disease is suspected; however, re-staging only by imaging can be inaccurate due to high false-negative and false-positive rates. New histological confirmation of the neoplasm should consider as mandatory when discussing indication to surgery.

Endobronchial ultrasound bronchoscopy (EBUS) is usually performed when radiological findings are suggestive for lymph nodes involvement. EBUS provides acceptable sensitivity and specificity of 67% and 99% respectively, with a low rate of complications. However, EBUS presents some limitations, such as the availability of equipment and expertise, and the occurrence of false-negative or false-positive results when aspirated mediastinal nodes are close to the mass (9). Nevertheless, EBUS should be considered as the preferred diagnostic procedure over mediastinoscopy when performing re-staging for locally advanced NSCLC. While mediastinoscopy is still a pillar in the algorithm of the European Society of Thoracic Surgery for the staging of NSCLC, its safety is dramatically reduced when the procedure is offered after few months from high-dose radiation on the mediastinum (10). In the future, innovative molecular medicine technologies could potentially facilitate early identification of local recurrence or residual malignancy after curative treatment. Assessment of circulating tumour cells plays an important role in defining potential benefits of salvage surgery since dissemination of the disease at the cellular level, is substantially associated with reduced progression-free survival and lower overall survival (11).

Furthermore, novel imaging techniques, such as PET/magnetic resonance imaging (MRI) could further improve diagnosis of recurrent tumour and differentiate it from fibrotic/inflammatory changes related to CT-RT, leading to a more accurate indication to surgical resection (12-15).

Selection criteria for salvage surgery can be summarized as follow:
- Patients fit for surgery: careful pre-operative cardiorespiratory evaluation;
- No other therapeutic options;
- Accurate Re-staging: new histological confirmation of viable tumour and absence of extrathoracic diseases (16).

Brief review

A retrospective analysis of 40 patients who underwent surgical resection after definitive CT-RT for NSCLC was reported by Sonett et al. (17). The median time between radiotherapy and surgery was two months. The authors reported a surprising no postoperative mortality. This was probably due to a careful patients’ selection criteria, different radiation technique, systematic coverage of bronchial stump after pneumonectomy and enhancements in the postoperative care.

Bauman and co-authors, in 2008 (18), retrospectively described the outcome of 24 patients recruited for surgery from 1997 to 2005. These patients were divided into three groups: patients in group A presented local relapse documented by CT scan, group B had only FGD-PET abnormalities, and group C were conversions to trimodally treatment. They concluded that surgery was feasible and that the survival was higher among patients who underwent resection for abnormal FDG-PET than for local relapse detected by CT scan. The results of this study underline the importance of pathological tissue confirmation before indicating salvage surgery. The diagnosis of residual disease
or recurrence on CT and PET-CT scans after CT-RT can be misleading, and we, therefore, believe that an attempt should be made to obtain pathological evidence of recurrent disease before indicating a high-risk surgical procedure.

In 2009, Cerfolio explored the topic of surgery after high dose radiation. In a retrospective study, they analysed the outcome of 216 patients, accrued over 10 years, and who underwent a previous median dose of radiation of 60 Gy (range, 60–72 Gy). They concluded that surgery was safe, with a reasonable complication rate. They reported two bronchopleural fistulas after right pneumonectomy and no fistulas after lobectomy. The bronchial stump was buttressed either intercostal flap or omentum. Older age, poor preoperative pulmonary function test and smoking history were statistically significantly associated with postoperative morbidity and operative mortality.

The authors also observed that re-do mediastinoscopy after radiation therapy of the mediastinum could be ineffective and unsafe (19).

The randomized multi-centric trial published by Albain et al. (20) was focused on comparing the overall survival of 202 patients diagnosed with T1-3pN2M0 NSCLC. Patients were randomly assigned in a 1:1 ratio to concurrent induction chemotherapy with cisplatin and etoposide plus radiotherapy (45 Gy). If no progression occurred, patients were divided into two groups: group 1 underwent resection, group 2 continued radiotherapy uninterrupted up to 61 Gy. Two cycles of adjuvant cisplatin and etoposide were administered in both groups. They concluded that overall survival was improved in the patients who underwent lobectomy, but not for patients who underwent pneumonectomy. However, neither of the two treatment options is significantly superior. The disease-free survival was worse in the non-surgical group while mortality related to the intervention was higher in the operative group.

Dickhoff and colleagues (21) in 2016, conducted a study of over 15 patients with clinical evidence of recurrence or persistent disease. Patients were scheduled for anatomical pulmonary resection, and 8 of them underwent pneumonectomy. The morbidity rate was as high as 40%, while the 90-day mortality rate was 6.7% (1 patient). The estimated median overall and event-free survivals were 46 and 43.6 months, respectively. The benefits and favourable long-term outcome of salvage surgery were also demonstrated by Uramoto et al. (22). The authors reported the outcomes of salvage operations performed in 16 patients; They found a 5-year overall survival rate in salvage surgery patients of 40.4% and they observed that salvage surgery could be performed safely with low morbidity rate and promising long-term survival.

In 2017, Casiraghi and co-authors (23) published the outcome of 35 patients, accrued over ten years, who underwent surgery for local recurrence after definitive CT-RT (58 Gy). In this study were included patients who underwent major resection (vascular sleeve, tracheal sleeve pneumonectomy, intrapericardial pneumonectomy, superior cava vein resection and reconstruction) and exploratory thoracotomies. The authors found that the survival rate was causally related to the R0 resection, with a median survival of 27 months in this group. They also reported a 30 days mortality of 5.7% (2 patients). On our opinion, these data underline the importance of preoperative workup to confirm radical resection (R0).

A systematic review of the literature published, again by Dickhoff in 2018, attempted to define better the management of patient scheduled for salvage surgery. The authors analyzed a total of 158 clinical cases from 8 retrospective studies. Patients included in these analyses were also those converted to trimodally treatment, and patients who underwent surgery for complications due to radiotherapy. The authors concluded that the limited data in support of salvage surgery after radical CT-RT are very heterogeneous with a low level of evidence. The apparent survival benefit of the patients undergoing surgery may be related to a selection bias. As the patients were fit, with limited disease, and a high chance of R0 resection. The overall 30- and 90-day mortality rate was high: 3% and 6.5% respectively (24) (Table 1).

The advent of immunotherapy for targeted ligands represent an ongoing “revolution” in the treatment of advanced pulmonary malignancies. The role of surgery in patients who received immunotherapy is still under investigation, and up to date, there are no consistent data available. Immunotherapy seems to cause an intense fibrotic reaction which makes subsequent surgical intervention more challenging and potentially may negatively affect postoperative morbidity.

**Limitations**

There are several a few limitations related to study. This is a narrative review and not a systematic review of the
literature. All data were collected retrospectively. Moreover, due to the small sample sizes, caution should be used in the interpretation of the results.

Conclusions

To date, there are weak and heterogeneous data on salvage surgery after curative-intent treatment of locally advanced NSCLC. Therefore, it is not possible to draw definitive conclusions. Salvage surgery is technically challenging, the anatomy is profoundly modified by the fibrotic reaction to chemo and radiotherapy, and extensive resections are often required to provide an R0 surgical margin.

A careful patient's selection and the surgical expertise allow for successful salvage lung resections with acceptable morbidity.

Substantial evidence needs to be produced, preferably be mean of randomized controlled trials and the procedure should be offered within the setting of a research protocol.

Acknowledgments

Funding: None.

Footnote

Provenance and Peer Review: This article was commissioned by the Guest Editors (Davide Tosi and Alessandro Palleschi) for the series “The Treatment of Locally Advanced Lung Cancer” published in Current Challenges in Thoracic Surgery. The article was sent for external peer review organized by the Guest Editors and the editorial office.

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/ccts-20-88). The series “The Treatment of Locally Advanced Lung Cancer” was commissioned by the editorial office without any funding or sponsorship. The authors have no other conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of this work in ensuring that questions related to the accuracy or integrity of any part of this work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

Table 1 Oncological outcome and surgical strategies of published studies of patients undergoing salvage surgery for advanced NSCLC

<table>
<thead>
<tr>
<th>Authors</th>
<th>Number of patients</th>
<th>Methods</th>
<th>Overall survival</th>
<th>Surgical procedures</th>
<th>Bronchial stump coverage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sonett et al. (17)</td>
<td>40</td>
<td>Retrospective analysis</td>
<td>56.4% at 5 years</td>
<td>Lobectomies and pneumonectomies</td>
<td>Systematic, intercostal flaps</td>
</tr>
<tr>
<td>Bauman et al. (18)</td>
<td>24</td>
<td>Retrospective analysis</td>
<td>Median OS 30 months</td>
<td>Wedge, Lobectomies, bilobectomies and pneumonectomies</td>
<td>Omental and/or muscle flaps</td>
</tr>
<tr>
<td>Albain et al. (20)</td>
<td>202</td>
<td>phase III randomised trial</td>
<td>Median OS 23.6 months</td>
<td>Wedge resections, lobectomies and pneumonectomies</td>
<td>_</td>
</tr>
<tr>
<td>Dickhoff et al. (21)</td>
<td>15</td>
<td>Retrospective analysis</td>
<td>Median OS 46 months</td>
<td>Lobectomies and pneumonectomies</td>
<td>_</td>
</tr>
<tr>
<td>Casiraghi et al. (23)</td>
<td>24</td>
<td>Retrospective analysis</td>
<td>37% at 3 years</td>
<td>Lobectomies, pneumonectomies, vascular resection</td>
<td>Not described</td>
</tr>
<tr>
<td>Uramoto et al. (22)</td>
<td>16</td>
<td>Retrospective analysis</td>
<td>40.4% at 5 years</td>
<td>Lobectomies and pneumonectomies</td>
<td>Pericardial fat tissue and/or intercostal muscle pedicle</td>
</tr>
</tbody>
</table>

NSCLC, non-small cell lung cancer; OS, overall survival.
References


22. Uramoto H, Nakajima Y, Kinoshita H, et al. Equivalent Outcome of Patients with Locally Advanced NSCLC Treated with Salvage Surgery Compared to Induction Chemotherapy Followed by Surgical Resection. Anticancer...


doi: 10.21037/ccts-20-88